2-{3-[6-(2-chloro-5-hydroxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenoxy}-acetamide | 1239954-81-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-{3-[6-(2-chloro-5-hydroxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenoxy}-acetamide
• 英文别名: 2-[3-[[6-(2-Chloro-5-hydroxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino]phenoxy]acetamide
• CAS: 1239954-81-4
• 化学式: C₂₀H₁₆ClN₅O₃
• 分子量: 409.832
• InChiKey: ZWTWEMOWSXHKJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] [1, 2, 4] TRIAZOLO [1, 5 -A] PYRIDINES AS KINASE INHIBITORS<br/>[FR] [1, 2, 4] TRIAZOLO [1, 5 -A] PYRIDINES SERVANT D'INHIBITEURS DE KINASES
  申请人：FOVEA PHARMACEUTICALS SA

  公开号：WO2010092041A1

  公开（公告）日：2010-08-19

  The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted triazolopyridine compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder. In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.

  这项发明涉及某些新型化合物、其生产方法以及治疗或缓解激酶介导的疾病的方法。更具体地说，这项发明涉及取代的三唑吡啶化合物，可用作选择性激酶抑制剂，制备这种化合物的方法以及治疗或缓解激酶介导的疾病的方法。特别是，这些方法与治疗或缓解激酶介导的疾病有关，包括心血管疾病、糖尿病、糖尿病相关疾病、炎症性疾病、免疫性疾病、癌症以及眼部疾病，如视网膜病变、黄斑变性或其他玻璃体视网膜疾病等。
• Heterocyclic compounds
  申请人：Leriche Caroline

  公开号：US20120041195A1

  公开（公告）日：2012-02-16

  The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted triazolopyridine compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder. In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.

  本发明涉及某些新型化合物，制备它们的方法以及治疗或改善激酶介导的疾病的方法。更具体地说，本发明涉及取代的三唑吡啶化合物，可用作选择性激酶抑制剂，制备这种化合物的方法以及治疗或改善激酶介导的疾病的方法。特别是，这些方法涉及治疗或改善激酶介导的疾病，包括心血管疾病、糖尿病、糖尿病相关疾病、炎症性疾病、免疫性疾病、癌症以及眼部疾病，如视网膜病变、黄斑变性或其他玻璃体视网膜疾病等。
• Ý1, 2, 4¨TRIAZOLO Ý1, 5 -A¨PYRIDINES AS KINASE INHIBITORS
  申请人：Fovea Pharmaceuticals

  公开号：EP2396324A1

  公开（公告）日：2011-12-21